Clinical Trials · NCT00742339

Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome

Name: Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

TerminatedPhase 2/Phase 3Octreotide

Phase: Phase 2/Phase 3
Recruitment status: Terminated
Sponsor: University of Padova
Enrollment: 49
Start date: May 2005
Locations: 1 site, Italy
Primary endpoint: The primary end-point of the study is the complete reform of the renal function (serum creatinine < 1.5 mg/dl. The primary end point will be evaluated at the end of the treatment.

View Octreotide compound reference